Patents by Inventor Patrick Shum

Patrick Shum has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COLONY STIMULATING FACTOR-1 RECEPTOR (CSF-1R) INHIBITORS
    Publication number: 20220396588
    Abstract: Compounds of the formulas which are useful as colony stimulating factor-1 receptor inhibitors (“CSF-1R inhibitors”).
    Type: Application
    Filed: February 9, 2022
    Publication date: December 15, 2022
    Applicant: Genzyme Corporation
    Inventors: John L. Kane, JR., Claude Barberis, Mark Czekaj, Paul Erdman, Barret Giese, Michael Kothe, Tieu-Binh Le, Jinyu Liu, Liang Ma, Markus Metz, Vinod Patel, Andrew Scholte, Patrick Shum, Linli Wei
  • Heterocyclic compounds as P2X7 ion channel blockers
    Patent number: 7741493
    Abstract: The present invention relates to a novel series of 4,5-diphenyl-2-amino-4,5-dihydro-imidazole derivatives of the formula II: wherein R, R1, R2, R3, R4, R5, X and Y are as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are P2X7 ion channel blockers and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases having an inflammatory component, including inflammatory bowel disease, rheumatoid arthritis and disease conditions associated with the central nervous system, such as stroke, Alzheimer's disease, etc.
    Type: Grant
    Filed: November 29, 2007
    Date of Patent: June 22, 2010
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Patrick Shum, Alexandre Gross, Liang Ma, Daniel G. McGarry, Gregory H. Merriman, David Rampe, Garth Ringheim, Jeffrey Stephen Sabol, Francis A. Volz
  • HETEROCYCLIC COMPOUNDS AS P2X7 ION CHANNEL BLOCKERS
    Publication number: 20080132550
    Abstract: The present invention relates to a novel series of 4,5-diphenyl-2-amino-4,5-dihydro-imidazole derivatives of the formula II: wherein R, R1, R2, R3, R4, R5, X and Y are as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are P2X7 ion channel blockers and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases having an inflammatory component, including inflammatory bowel disease, rheumatoid arthritis and disease conditions associated with the central nervous system, such as stroke, Alzheimer's disease, etc.
    Type: Application
    Filed: November 29, 2007
    Publication date: June 5, 2008
    Applicant: AVENTIS PHARMACEUTICALS INC.
    Inventors: Patrick SHUM, Alexandre GROSS, Liang MA, Daniel G. MCGARRY, Gregory H. MERRIMAN, David RAMPE, Garth RINGHEIM, Jeffrey Stephen SABOL, Francis A. VOLZ
  • Heterocyclic compounds as P2X7 ion channel blockers
    Patent number: 7326792
    Abstract: The present invention relates to a novel series of 4,5-diphenyl-2-amino-4,5-dihydro-imidazole derivatives of the formula II: wherein R, R1, R2, R3, R4, R5, X and Y are as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are P2X7 ion channel blockers and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases having an inflammatory component, including inflammatory bowel disease, rheumatoid arthritis and disease conditions associated with the central nervous system, such as stroke, Alzheimer's disease, etc.
    Type: Grant
    Filed: July 21, 2004
    Date of Patent: February 5, 2008
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Patrick Shum, Alexandre Gross, Liang Ma, Daniel G. McGarry, Gregory H. Merriman, David Rampe, Garth Ringheim, Jeffrey Stephen Sabol, Francis A. Volz
  • Pyrazoles as inhibitors of tumor necrosis factor
    Publication number: 20060063796
    Abstract: The present invention provides compounds of Formula (I) and ester prodrugs, pharmaceutically acceptable salts or solvates of such compounds; or ester prodrugs of such salts or solvates; pharmaceutical compositions comprising such compounds, their preparation, and their pharmaceutical use in the treatment of disease states capable of being modulated by the inhibition of p38 kinase and/or tumor necrosis factor (TNF).
    Type: Application
    Filed: November 1, 2005
    Publication date: March 23, 2006
    Applicant: Aventis Pharmaceuticals Inc.
    Inventors: David Borcherding, Alexandre Gross, Patrick Shum, Nicole Willard, Brian Freed
  • Heterocyclic compounds as P2X7 ion channel blockers
    Publication number: 20050026916
    Abstract: The present invention relates to a novel series of 4,5-diphenyl-2-amino-4,5-dihydro-imidazole derivatives of the formula II: wherein R, R1, R2, R3, R4, R5, X and Y are as defined herein. This invention also relates to methods of making these compounds. The compounds of this invention are P2X7 ion channel blockers and are therefore useful as pharmaceutical agents, especially in the treatment and/or prevention of a variety of diseases having an inflammatory component, including inflammatory bowel disease, rheumatoid arthritis and disease conditions associated with the central nervous system, such as stroke, Alzheimer's disease, etc.
    Type: Application
    Filed: July 21, 2004
    Publication date: February 3, 2005
    Applicant: Aventis Pharmaceuticals Inc.
    Inventors: Patrick Shum, Alexandre Gross, Liang Ma, Daniel McGarry, Gregory Merriman, David Rampe, Garth Ringheim, Jeffrey Sabol, Francis Volz